Key facts
- It has raised $19.1M across 3 recorded rounds; the latest was Seed Round ($1.1M) in Jan 2025.
- Notable investors include Elevate Ventures, IU Ventures.
- BioPoly has filed 9 Form Ds with the SEC since 2009, most recently Feb 2025 ($1.1M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioPoly
Funding rounds
3 roundsAbout BioPoly
Developer and manufacturer of orthopedic devices designed to provide a treatment option for painful cartilage lesions. The company's devices are made of patented material which is a combination of hyaluronic acid and polyethylene (UHMWPE), that provides a self-lubricated surface to replace damaged cartilage, thus, eliminating painful joints, enabling patients to quickly recover and return to pain-free, active lifestyles.
- Sector
- Healthcare
- HQ
- Fort Wayne, IN, United States
- Employees
- 9
- Website
- biopolyortho.com/
- Ownership
- Privately Held (backing)
BioPoly doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioPoly shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioPoly in its N-PORT filings yet. We sweep new filings monthly.